Schrum Private Wealth Management LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

Schrum Private Wealth Management LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 54.1% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 14,354 shares of the biopharmaceutical company’s stock after selling 16,948 shares during the quarter. Schrum Private Wealth Management LLC’s holdings in Pfizer were worth $381,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Swedbank AB grew its stake in shares of Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after acquiring an additional 37,636 shares during the period. Moloney Securities Asset Management LLC raised its stake in Pfizer by 37.8% in the third quarter. Moloney Securities Asset Management LLC now owns 21,086 shares of the biopharmaceutical company’s stock valued at $610,000 after purchasing an additional 5,785 shares in the last quarter. Cary Street Partners Asset Management LLC lifted its holdings in shares of Pfizer by 7.0% during the 3rd quarter. Cary Street Partners Asset Management LLC now owns 18,865 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 1,238 shares during the last quarter. Hanlon Investment Management Inc. bought a new stake in Pfizer during the third quarter worth about $205,000. Finally, NorthRock Partners LLC boosted its stake in Pfizer by 2.0% in the third quarter. NorthRock Partners LLC now owns 25,102 shares of the biopharmaceutical company’s stock worth $726,000 after buying an additional 497 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on PFE shares. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wolfe Research started coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Up 0.7 %

PFE stock opened at $25.93 on Thursday. The business’s 50-day moving average is $26.31 and its two-hundred day moving average is $27.27. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $146.93 billion, a price-to-earnings ratio of 18.39, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the firm earned $0.10 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.63%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 121.99%.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.